HCW Biologics entered into a securities purchase agreement with accredited investors for a private placement expected to generate approximately $1.6 million in gross proceeds. The company will use the net proceeds for working capital, general corporate purposes, and to continue its clinical development activities.
Key Details
- Offering Structure: The company will sell 618,682 units, each consisting of one share of common stock (or a pre-funded warrant) and a common warrant to purchase one share of common stock.
- Financial Terms: Units were sold at $2.585 each. The common warrants, subject to stockholder approval, will have an exercise price of $2.585 per share and a 5.5-year term. The pre-funded warrants have an exercise price of $0.0001 per share.
- Insider Participation: CEO Hing C. Wong, Chairman of the Board Scott Garrett, and SVP of Business Development Lee Flowers participated in the private placement on the same terms as other investors.